Developing Oral Biologics to Treat Disease at its Origin
At any given time, over 70% of an individual’s immune system resides in the lamina propria, which is the target-rich tissue of the intestinal tract. With privileged access to the immune-cell rich GI environment, AMT’s lead product candidates are designed to intercept disease biology at critical sites by directly targeting signaling axes within the GI tract.
AMT has a robust pipeline of oral biologic product opportunities engineered to gain privileged access to the immune system and the hepatic portal system by crossing intestinal epithelial barriers. This privileged access provides the opportunity to address disease at its point of origin and creates the potential to achieve greater efficacy and tolerability than seen with parenterally administered therapeutics, particularly in the areas of immunology and inflammation, liver and metabolic diseases.